Novo Nordisk Logo

Novo Nordisk

Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.

NOVO | CO

Overview

Corporate Details

ISIN(s):
DK0062498333 (+1 more)
LEI:
549300DAQ1CVT6CXN342
Country:
Denmark
Address:
Novo Alle 1, 2880 Bagsværd
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures innovative biological medicines and therapeutic devices. With a focus on driving change to defeat serious chronic diseases, the company's primary treatment areas include diabetes, obesity, and rare blood and endocrine disorders. Leveraging over 90 years of innovation, Novo Nordisk provides pharmaceutical products and services to patients worldwide, aiming to make its treatments accessible and improve health outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 14:58
Director's Dealing
English 16.2 KB
2025-11-17 14:58
Regulatory News Service
English 123.6 KB
2025-11-11 14:39
Director's Dealing
English 26.7 KB
2025-11-11 14:39
Regulatory News Service
English 155.6 KB
2025-11-06 19:01
Regulatory News Service
English 143.7 KB
2025-11-06 19:01
Regulatory News Service
English 6.0 KB
2025-10-30 10:49
M&A Activity
English 74.8 KB
2025-10-30 10:49
M&A Activity
English 5.3 KB
2025-10-21 13:56
Board/Management Information
English 7.2 KB
2025-10-21 13:56
Board/Management Information
English 78.0 KB
2025-10-09 12:00
M&A Activity
English 12.9 KB
2025-10-09 12:00
M&A Activity
English 124.0 KB
2025-09-10 07:00
Regulatory News Service
English 11.2 KB
2025-09-10 07:00
Earnings Release
English 151.5 KB
2025-08-19 13:37
Director's Dealing
English 17.4 KB

Automate Your Workflow. Get a real-time feed of all Novo Nordisk filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Novo Nordisk

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Novo Nordisk via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Assertio Holdings, Inc. Logo
Offers branded prescription drugs for neurology, pain, and CNS to US patients.
United States of America
ASRT
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan
4503
Astena Holdings Co., Ltd. Logo
Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.
Japan
8095
AstraZeneca PLC Logo
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
United Kingdom
AZN
Astria Therapeutics, Inc. Logo
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
ATAI Life Sciences N.V. Logo
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
Atara Biotherapeutics, Inc. Logo
Pioneering off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
Atea Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
Athira Pharma, Inc. Logo
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS

Talk to a Data Expert

Have a question? We'll get back to you promptly.